Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 -0.11%79 Receivables Turnover is 0.87 as of Jun. 2026. GuruFocus rates SHSE:603387 with a GF Score™ of 79/100 and a GF Value™ of ¥8.02 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Getein Biotech ranks worse than 85.59% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Getein Biotech's Revenue for the
three
months ended in Jun. 2026 was ¥288 Mil. Getein Biotech's average Accounts Receivable for the
three
months ended in Jun. 2026 was ¥329 Mil.
Hence, Getein Biotech's Receivables Turnover for the
three
months ended in Jun. 2026 was 0.87.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Getein Biotech Receivables Turnover Related Terms
Getein Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Getein Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603387 vs ABT, SYK, MDT: Receivables Turnover Comparison
For the Medical Devices subindustry, Getein Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech Receivables Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Getein Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getein Biotech (SHSE:603387) has a Receivables Turnover of 0.87 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Getein Biotech and its competitors. According to the industry distribution chart, Getein Biotech ranks #695 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 85.6%.
Is Getein Biotech's Receivables Turnover too high?
Getein Biotech's current Receivables Turnover is 0.87. The Medical Devices & Instruments industry median Receivables Turnover is 5.58. Getein Biotech's value of 0.87 is 84.4% below this industry median. Based on the distribution chart, Getein Biotech ranks #695 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Getein Biotech has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's Receivables Turnover compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #695 out of 812 companies for Receivables Turnover. This places Getein Biotech in the lower half of its industry. The industry median Receivables Turnover is 5.58. Getein Biotech's value of 0.87 is 84.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Devices & Instruments company?
The median Receivables Turnover among Medical Devices & Instruments companies is 5.58, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getein Biotech's current Receivables Turnover of 0.87 is 84.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Getein Biotech and its competitors. For the Medical Devices & Instruments industry, the median Receivables Turnover is 5.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getein Biotech's current Receivables Turnover is 0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥8.02, compared to a current price of ¥9.32 — trading 16.2% above its estimated fair value. The current Receivables Turnover is 0.87 and 84.4% below the Medical Devices & Instruments industry median of 5.58. Getein Biotech's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current Receivables Turnover is 0.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥9.32 is trading 16.2% above its estimated GF Value™ of ¥8.02.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
Receivables Turnover: 0.87
GF Value™: ¥8.02 vs. price of ¥9.32 (16.2% above fair value)
Industry Position: 84.4% below the Medical Devices & Instruments median (#695 of 812)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
79GF Score
Get the complete analysis for SHSE:603387
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
